More than anything, conversations like this are why we built MedNews Week — to learn from those not just advancing oncology, but redefining how we think about it.

What stood out wasn’t just the content, but the clarity of thought. The ability to distill complex, rapidly evolving science into frameworks that actually move clinical care forward is rare — and that came through throughout.

Dr. Chua’s work in nasopharyngeal cancer has helped shape clinical trials and inform practice worldwide — a voice that carries well beyond any single institution.

Kicking things off with Dr. Melvin L.K. Chua, a globally recognized radiation oncologist and leader in precision oncology, whose perspective reflects exactly where the field is heading — data-driven care, biomarker-guided strategies, and true international collaboration.

Precision at the Core: Advancing Nasopharyngeal Carcinoma Care with Proton Beam Therapy | Episode 1 Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.

Excited to launch the 1st episode of the MedNews Week × OncoDaily partnership — built around one idea: global oncology education without borders 🌍

Tune in: lnkd.in/gUyXam9B

Shuf.ai Shuf turns any medical content into a new format with AI so that you can increase your audience

From CRS to ICANS, this episode reframes how we think about risk, monitoring, and the future of cellular therapy.

This isn’t just about side effects—it’s about redefining the limits of innovation.

🎧 Tune in: www.shuf.ai/episode-play...

Shuf.ai Shuf turns any medical content into a new format with AI so that you can increase your audience

CAR-T therapy has transformed oncology—but toxicity remains its biggest limitation.

In Episode 6 of The Translational Edge, we break down one of the most important questions in the field today:

Can we push efficacy further without breaking safety?

Rewriting the Hemoglobin Switch: CRISPR Targeting in Sickle Cell Disease | CancerNetwork The RUBY trial demonstrates that disrupting the BCL11A binding site in the γ-globin promoters can normalize hemoglobin in severe sickle cell disease.

Worth the read if you’re following where hematology—and gene therapy—is heading:

www.cancernetwork.com/view/rewriti...

#OncTwitter #HemeTwitter #GeneTherapy #CRISPR #SickleCell #Hematology

Rewriting the Hemoglobin Switch: CRISPR Targeting in Sickle Cell Disease | CancerNetwork The RUBY trial demonstrates that disrupting the BCL11A binding site in the γ-globin promoters can normalize hemoglobin in severe sickle cell disease.

Targeting regulators like BCL11A is elegant.

Making it durable, scalable, and accessible is the real challenge.

This is where curative intent becomes tangible.

Rewriting the Hemoglobin Switch: CRISPR Targeting in Sickle Cell Disease | CancerNetwork The RUBY trial demonstrates that disrupting the BCL11A binding site in the γ-globin promoters can normalize hemoglobin in severe sickle cell disease.

Thank you to Cancer Network for the feature.

Rewriting the Hemoglobin Switch: CRISPR Targeting in Sickle Cell Disease

Gene editing has moved from concept to clinic.

By leveraging CRISPR to reactivate fetal hemoglobin, we’re no longer just managing SCD—we’re aiming to rewrite its biology.

Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma | CancerNetwork The next frontier is not only building constructs that reduce one mechanism of relapse, but understanding why antigen-positive failures still occur.

Worth the read if you care about where lymphoma therapy is heading.

www.cancernetwork.com/view/rethink...

#OncTwitter #CAR-T #Lymphoma #Immunotherapy

Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma | CancerNetwork The next frontier is not only building constructs that reduce one mechanism of relapse, but understanding why antigen-positive failures still occur.

Relapse still defines the field.
Dual targeting aims to change that.
But durability isn’t just about antigen escape.
Even antigen-positive disease can fail.

This is the next frontier:
Not just building better CARs—but understanding why remissions don’t last.

Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma | CancerNetwork The next frontier is not only building constructs that reduce one mechanism of relapse, but understanding why antigen-positive failures still occur.

Thank you to Cancer Network for highlighting:

Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma
CAR T works—but not for everyone.

Thank you

Jeremy Bellaiche: Episode 5 of The Translational Edge With Yan Leyfman on Exercise in Cancer Care - OncoDaily Jeremy Bellaiche: Episode 5 of The Translational Edge With Yan Leyfman on Exercise in Cancer Care / cancer, Jeremy Bellaiche, OncoDaily, Oncology, The

Episode 5 of The Translational Edge With Yan Leyfman on Exercise in Cancer Care - Jeremy Bellaiche

@yleyfman.bsky.social

oncodaily.com/voices/yan-l...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Thank you

Shuf.ai Shuf turns any medical content into a new format with AI so that you can increase your audience

From muscle signaling to tumor microenvironment modulation, this is where lifestyle meets translational science.

🎧 Tune in: www.shuf.ai/episode-play...

Let me know what surprised you most.

Exercise isn’t just supportive care anymore—it’s becoming therapeutic.

In the latest episode of The Translational Edge, we explore how exercise is quietly reshaping cancer care—impacting outcomes, biology, and survivorship in ways we’re only beginning to understand.

Reprogramming T Cells: The Promise of In Vivo Site-Specific CAR Engineering | CancerNetwork A landmark Nature study demonstrates targeted CRISPR-based CAR transgene integration in living patients' T cells without ex vivo manufacturing.

www.cancernetwork.com/view/reprogr...

Reprogramming T Cells: The Promise of In Vivo Site-Specific CAR Engineering | CancerNetwork A landmark Nature study demonstrates targeted CRISPR-based CAR transgene integration in living patients' T cells without ex vivo manufacturing.

Thank you to Cancer Network for highlighting:

Reprogramming T Cells: The Promise of In Vivo Site-Specific CAR Engineering
CAR T therapy—without the lab.

A single infusion.
Precise genome integration.
T cells engineered in vivo.
This is how we scale cellular therapy.

Thank you

Thank you

When the World Stopped: A Lesson in Strength and Second Chances | CancerNetwork Yan Leyfman, MD, reflected on resilience and hope in the face of cancer, recounting a 37-year-old diagnosed with stage IV colorectal cancer followed by HIV.

Thank you to Cancer Network for highlighting my latest piece:

When the World Stopped: A Lesson in Strength and Second Chances

A reflection on resilience, perspective, and what oncology teaches us when time stands still.

www.cancernetwork.com/view/when-th...

This is only the beginning.

The best is yet to come.

@oncodaily.bsky.social

Together, we are creating a space that not only shares knowledge—but builds leaders, fosters global collaboration, and shines a light on talent across every corner of the world.

Our mission remains unchanged.

We are MedNews Week — connecting medicine, globally.

MedNews Week is proud to announce our partnership with OncoDaily.

This collaboration marks an exciting step forward as we continue to expand our platform, amplify our mission, and elevate the voices shaping the future of oncology and medicine worldwide.

Honored to be included in this outstanding group of innovators. It is especially meaningful to be recognized alongside colleagues and mentors who have helped shape the next generation of oncology.

x.com/HemOncToday/...

MedNews Week remains deeply committed to amplifying the voices of women leaders in medicine globally.
#InternationalWomensDay #WomenInMedicine #MedNewsWeek #WomenInScience #PhysicianLeadership

Happy International Women’s Day to these remarkable leaders — and to women in medicine everywhere. 🌍💜
Grateful to learn from you all.

Your leadership advances patient care, drives discovery, and empowers others to push medicine forward.
Thank you for your mentorship, your brilliance, and for continuously lifting others along the way.